EUVIMEDEUVIMED entdecken
Open Access

Drug to genome to drug: a computational large-scale chemogenomics screening for novel drug candidates against sporotrichosis

Andressa Santana Santos, Vinícius Alexandre Fiaia Costa, Vivianny Aparecida Queiroz Freitas, Laura Raniere Borges Dos Anjos, Eder Soares de Almeida Santos, Thales Domingos Arantes, Carolina Rodrigues Costa, Ana Laura de Sene Amâncio Zara, Maria do Rosário Rodrigues Silva, Bruno Junior Neves

Brazilian Journal of Microbiology · 2024

DOI: 10.1007/s42770-024-01406-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brazilian Journal of Microbiology, 2024. Verfasst von Andressa Santana Santos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, Goiás, Brazil. Hauptthemen laut MEDLINE: Sporothrix, Antifungal Agents, Sporotrichosis, Microbial Sensitivity Tests. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FAPEG, Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sporotrichosis is recognized as the predominant subcutaneous mycosis in South America, attributed to pathogenic species within the Sporothrix genus. Notably, in Brazil, Sporothrix brasiliensis emerges as the principal species, exhibiting significant sapronotic, zoonotic and enzootic epidemic potential. Consequently, the discovery of novel therapeutic agents for the treatment of sporotrichosis is imperative. The present study is dedicated to the repositioning of pharmaceuticals for sporotrichosis therapy. To achieve this goal, we designed a pipeline with the following steps: (a) compilation and preparation of Sporothrix genome data; (b) identification of orthologous proteins among the species; (c) identification of homologous proteins in publicly available drug-target databases; (d) selection of Sporothrix essential targets using validated genes from Saccharomyces cerevisiae; (e) molecular modeling studies; and (f) experimental validation of selected candidates. Based on this approach, we were able to prioritize eight drugs for in vitro experimental validation. Among the evaluated compounds, everolimus and bifonazole demonstrated minimum inhibitory concentration (MIC) values of 0.5 µg/mL and 4.0 µg/mL, respectively. Subsequently, molecular docking studies suggest that bifonazole and everolimus may target specific proteins within S. brasiliensis- namely, sterol 14-α-demethylase and serine/threonine-protein kinase TOR, respectively. These findings shed light on the potential binding affinities and binding modes of bifonazole and everolimus with their probable targets, providing a preliminary understanding of the antifungal mechanism of action of these compounds. In conclusion, our research advances the understanding of the therapeutic potential of bifonazole and everolimus, supporting their further investigation as antifungal agents for sporotrichosis in prospective hit-to-lead and preclinical investigations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SporothrixAntifungal AgentsSporotrichosisMicrobial Sensitivity TestsDrug RepositioningGenome, FungalBrazilFungal ProteinsMolecular Docking SimulationGenomicsHumansDrug Evaluation, PreclinicalDrug DiscoveryComputational Biology

Stichwörter der Autor:innen

Sporothrix brasiliensisDrug repurposingEverolimusSporotrichosisStructural bioinformatics

Substanzen

Antifungal AgentsFungal Proteins

Autor:innen und Institutionen

  • Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, Goiás, Brazil.
  • Laboratory of Cheminformatics, Faculty of Pharmacy, Federal University of Goiás, Goiânia, Goiás, Brazil.
  • Postgraduate Program in Health Technology Assistance and Assessment (PPG-AAS), Faculty of Pharmacy, Federal University of Goiás, Goiânia, Goiás, Brazil.
  • Laboratory of Cheminformatics, Faculty of Pharmacy, Federal University of Goiás, Goiânia, Goiás, Brazil. brunoneves@ufg.br.

Förderung

  • FAPEG
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

Zitieren

APA

Santos, A. S., Costa, V. A. F., Freitas, V. A. Q., Dos Anjos, L. R. B., de Almeida Santos, E. S., Arantes, T. D., Costa, C. R., de Sene Amâncio Zara, A. L., do Rosário Rodrigues Silva, M., & Neves, B. J. (2024). Drug to genome to drug: a computational large-scale chemogenomics screening for novel drug candidates against sporotrichosis. Brazilian Journal of Microbiology. https://doi.org/10.1007/s42770-024-01406-x

Vancouver

Santos AS, Costa VAF, Freitas VAQ, Dos Anjos LRB, de Almeida Santos ES, Arantes TD, et al. Drug to genome to drug: a computational large-scale chemogenomics screening for novel drug candidates against sporotrichosis. Brazilian Journal of Microbiology. 2024. doi:10.1007/s42770-024-01406-x

BibTeX
@article{Santos2024,
  author = {Santos, Andressa Santana and Costa, Vinícius Alexandre Fiaia and Freitas, Vivianny Aparecida Queiroz and Dos Anjos, Laura Raniere Borges and de Almeida Santos, Eder Soares and Arantes, Thales Domingos and Costa, Carolina Rodrigues and de Sene Amâncio Zara, Ana Laura and do Rosário Rodrigues Silva, Maria and Neves, Bruno Junior},
  title = {Drug to genome to drug: a computational large-scale chemogenomics screening for novel drug candidates against sporotrichosis},
  journal = {Brazilian Journal of Microbiology},
  year = {2024},
  doi = {10.1007/s42770-024-01406-x}
}
Kostenlos starten →